Trial reportThe Journal of clinical endocrinology and metabolism2011
Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.
Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.The Cochrane database of systematic reviews · 2023Pooled it
- Vitamin D for the management of multiple sclerosis.The Cochrane database of systematic reviews · 2018Pooled it
- Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia.The Cochrane database of systematic reviews · 2018Pooled it
- Vitamin D supplementation for prevention of mortality in adults.The Cochrane database of systematic reviews · 2014Pooled it
- Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.PloS one · 2013Pooled it
- Randomized trial of daily high-dose vitamin DNeurology · 2019Trial
- Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial.The Journal of clinical endocrinology and metabolism · 2016Trial
- Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.Neurology · 2016Trial
- The Effectiveness of Vitamin D Intake in Improving Symptoms and Relapses of Multiple Sclerosis: A Systematic Review.Cureus · 2024Review
- Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.Journal of neurology · 2024Article
- Review
- Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications.Brain communications · 2022Review
- The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency.PloS one · 2021Article
- Vitamin D in COVID - 19: Dousing the fire or averting the storm? - A perspective from the Asia-Pacific.Osteoporosis and sarcopenia · 2020Review
- Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis.British journal of pharmacology · 2020Review
- Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis.Frontiers in immunology · 2018Review
- Article
- Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects.Eating and weight disorders : EWD · 2017Review
- Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential.Frontiers in immunology · 2016Review
- Update in vitamin D and multiple sclerosis.Neurosciences (Riyadh, Saudi Arabia) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
contextThe active metabolite of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], is a potent modulator of immune cells in vitro.
objectiveOur objective was to determine whether the sun-dependent nutrient, cholecalciferol, can alter disease-associated cellular immune abnormalities in patients with multiple sclerosis (MS).
designThis was an open-label, 12-month, randomized controlled trial.
settingPatients with MS were recruited from the MS Clinic at St. Michael's Hospital, Toronto. PATIENTS: Forty-nine patients were matched (for age, sex, disease duration, disease-modifying drug, and disability) and enrolled (treated n = 25; control n = 24). Four patients were lost to follow-up (n = 2 from each group).
interventionTreated patients received increasing doses of cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to a moderate, physiological intake (10,000 IU/d). Control patients did not receive supplements.
main outcome measuresAt enrollment and at 12 months, peripheral blood mononuclear cell (PBMC) proliferative responses to disease-associated, MS-relevant, and control antigens were measured, along with selected serum biochemical markers.
resultsAt 12 months, mean serum 25-hydroxyvitamin D [25(OH)D] concentrations were 83 ± 35 nmol/liter and 179 ± 76 nmol/liter in control and treated participants, respectively (paired t, P < 0.001). Serum 1,25(OH)(2)D did not differ between baseline and 1 yr. In treated patients, 12-month PBMC proliferative responses to neuron antigens myelin basic protein and exon-2 were suppressed (P = 0.002). In controls, there were no significant changes in disease-associated PBMC responsiveness. There were no significant differences between groups in levels of selected biomarkers.
interpretationMS-associated, abnormal T cell reactivities were suppressed in vivo by cholecalciferol at serum 25(OH)D concentrations higher than 100 nmol/liter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.